Favipiravir versus other antiviral or standard of care for COVID-19 treatment: a rapid systematic review and meta-analysis

Favipiravir versus other antiviral or standard of care for COVID-19 treatment: a rapid systematic review and meta-analysis

Abstract Background The COVID-19 causing coronavirus is an enveloped RNA virus that utilizes an enzyme RNA dependent RNA polymerase for its replication. Favipiravir (FVP) triphosphate, a purine nucleoside analog, inhibits that enzyme. We have conducted this systematic review and meta-analysis on eff...

Full description

Bibliographic Details
Main Authors: Dhan Bahadur Shrestha, Pravash Budhathoki, Sitaram Khadka, Prajwol Bikram Shah, Nisheem Pokharel, Prama Rashmi
Format: Article
Language:English
Published: BMC 2020-09-01
Series:Virology Journal
Subjects:
Antiviral agents
COVID-19
COVID-19 drug treatment
Favipiravir
Severe acute respiratory syndrome coronavirus-2
Online Access:http://link.springer.com/article/10.1186/s12985-020-01412-z

Internet

http://link.springer.com/article/10.1186/s12985-020-01412-z

Similar Items